Synthesis, Characterization, and Pharmacokinetic Studies of Thiazolidine-2, 4-Dione Derivatives. (16th January 2023)

• Record Type: Journal Article
• Authors: Ansari, Bushra; Khan, Haroon; Jan, Muhammad Saeed; Alsharif, Khalaf F.; Alzahrani, Khalid J.; Rashid, Umer; Pirzada, Abdul Saboor
• Other Names: Tiwari Vinod Kumar Academic Editor.
• Is Part Of: Journal of chemistry. Volume 2023(2023)
• Publication Date: 2023-01-16
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1155/2023/9462176
• Languages: English
• ISSNs: 2090-9063

Abstract

Abstract : Various derivatives of thiazolidine-2, 4-dione (C1–C5) were designed and synthesized by chemical reaction with 4-nitrobenzaldehyde using Knoevenagel reaction conditions which results in the reduction of nitro group to amine and further modification results in target compounds. The chemical structures of all the 2, 4-thiazolidinedione derivatives have been elucidated by 1 H and 13 C NMR spectroscopy. These compounds were further characterized by in silico ADME (absorption, distribution, metabolism, and excretion) studies. The pharmacokinetic properties were assessed by SwissADME software. The in silico ADME (absorption, distribution, metabolism, and excretion) assessment reveals that all derivatives (C1 to C5) have 5 to 7 rotatable bonds. Lipophilicity and water solubility showed that C1, C2, and C4 are water soluble except for C3 and C5 which are moderately soluble. All the compounds have high GI absorption except C3. None of the derivatives are blood-brain barrier permeant. Drug metabolism of TZDs derivatives showed that C3 was identified as an inhibitor of CYP2C9 and C5 as an inhibitor of CYP1A2 and CYP2C19. Drug likeness properties indicate that C1 has only one violation of the Ghose rule while C3 has violations in the Ghose and Egan rules. The in silico pharmacokinetic studies revealed high GI absorption and the inability to pass blood-brain barrier which can be further assessed by in vitro and in vivo antihyperglycemic activity. This study will contribute to providing TZDs derivatives with an improved pharmacokinetic profile and decreased toxicity.